SummaryAs per the Kansas Department of Health and Environment reports, the Tuberculosis outbreak had spread in 2023, where the active cases were at 51, which jumped to 109 in 2024. It has continued even in 2025.
SummaryWith FDA approval, Zevaskyn is set to be a game-changer in the treatment of recessive dystrophic epidermolysis bullosa—offering patients more than just relief, but a meaningful step toward healing.